International Stem Cell Corp. (OTCMKTS:ISCO – Get Free Report)’s stock price passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.16 and traded as high as $0.20. International Stem Cell shares last traded at $0.20, with a volume of 66,372 shares traded.
International Stem Cell Trading Up 13.3%
The stock has a market capitalization of $1.60 million, a P/E ratio of -3.33 and a beta of -0.01. The stock’s 50 day simple moving average is $0.17 and its 200 day simple moving average is $0.16.
International Stem Cell (OTCMKTS:ISCO – Get Free Report) last released its earnings results on Thursday, May 14th. The biotechnology company reported ($0.03) earnings per share for the quarter. The firm had revenue of $2.32 million for the quarter.
International Stem Cell Company Profile
International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.
In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.
Featured Stories
- Five stocks we like better than International Stem Cell
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for International Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.
